<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-08-29">29 August 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Patrick</forename><forename type="middle">M</forename><surname>Moriarty</surname></persName>
							<email>pmoriart@kumc.edu</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Division of Clinical Pharmacology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Rainbow Blvd</orgName>
								<orgName type="institution">University of Kansas Medical Center</orgName>
								<address>
									<postCode>3901, 66160</postCode>
									<settlement>Kansas City</settlement>
									<region>KS</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Klaus</forename><forename type="middle">G</forename><surname>Parhofer</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Medical Department II</orgName>
								<orgName type="institution">University Munich</orgName>
								<address>
									<addrLine>Marchioninistraße 15</addrLine>
									<postCode>81377</postCode>
									<settlement>Grosshadern, Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><forename type="middle">P</forename><surname>Babirak</surname></persName>
							<affiliation key="aff2">
								<orgName type="institution">Metabolic Leader, LLC</orgName>
								<address>
									<addrLine>71 US Route 1 Suite J</addrLine>
									<postCode>04074-9375</postCode>
									<settlement>Scarborough</settlement>
									<region>ME</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marc-Andre</forename><surname>Cornier</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Division of Endocrinology, Metabolism and Diabetes</orgName>
								<orgName type="institution">Anschutz Health and Wellness Center-Anschutz Medical Campus</orgName>
								<address>
									<postCode>80045</postCode>
									<settlement>Aurora</settlement>
									<region>CO</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">P</forename><forename type="middle">Barton</forename><surname>Duell</surname></persName>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">Knight Cardiovascular Institute</orgName>
								<orgName type="institution" key="instit2">Oregon Health and Science University</orgName>
								<address>
									<addrLine>3181 SW Sam Jackson Park Road, L607</addrLine>
									<postCode>97239</postCode>
									<settlement>Portland</settlement>
									<region>OR</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bernd</forename><surname>Hohenstein</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of Internal Medicine III</orgName>
								<orgName type="institution" key="instit1">Extracorporeal Treatment and Lipoprotein Apheresis Center</orgName>
								<orgName type="institution" key="instit2">University Hospital Carl Gustav Carus</orgName>
								<orgName type="institution" key="instit3">Technische Universitaet Dresden</orgName>
								<address>
									<postCode>01069</postCode>
									<settlement>Dresden</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Josef</forename><surname>Leebmann</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Apherese Zentrum Passau</orgName>
								<address>
									<addrLine>Innstrasse 76</addrLine>
									<postCode>94032</postCode>
									<settlement>Passau</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Ramlow</surname></persName>
							<affiliation key="aff7">
								<orgName type="institution">Apheresis Centrum Rostock</orgName>
								<address>
									<addrLine>Nobelstr. 53</addrLine>
									<postCode>18059</postCode>
									<settlement>Rostock</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Volker</forename><surname>Schettler</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Apheresis Centre</orgName>
								<orgName type="institution">Nehrologisches Zentrum Go ¨ttingen GbR</orgName>
								<address>
									<addrLine>An der Lutter 24</addrLine>
									<postCode>D-37075</postCode>
									<settlement>Go ¨ttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Vinaya</forename><surname>Simha</surname></persName>
							<affiliation key="aff9">
								<orgName type="institution">Mayo Clinic</orgName>
								<address>
									<addrLine>200 First Street SW</addrLine>
									<postCode>55905</postCode>
									<settlement>Rochester, Rochester</settlement>
									<region>MN</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elisabeth</forename><surname>Steinhagen-Thiessen</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">Charite-Universit€ atsmedizin Berlin-Campus Virchow-Klinikum</orgName>
								<address>
									<addrLine>Augustenburger Platz 1, Ostring 3</addrLine>
									<postCode>13353</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><forename type="middle">D</forename><surname>Thompson</surname></persName>
							<affiliation key="aff11">
								<orgName type="institution">Hartford Hospital</orgName>
								<address>
									<addrLine>80 Seymour Street</addrLine>
									<postCode>JB722, 06102</postCode>
									<settlement>Cardiology, Hartford</settlement>
									<region>CT</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anja</forename><surname>Vogt</surname></persName>
							<affiliation key="aff12">
								<orgName type="laboratory">LMU Klinikum</orgName>
								<orgName type="institution" key="instit1">Medizinische Klinik und Poliklinik IV</orgName>
								<orgName type="institution" key="instit2">Universit€ at Mu ¨nchen</orgName>
								<address>
									<postCode>81377</postCode>
									<settlement>Munich</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Berndt</forename><surname>Von Stritzky</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Medical Department</orgName>
								<orgName type="institution">Sanofi-Aventis Deutschland GmbH</orgName>
								<address>
									<addrLine>Potsdamer Straße 8</addrLine>
									<postCode>10785</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yunling</forename><surname>Du</surname></persName>
							<affiliation key="aff14">
								<orgName type="institution">Regeneron Pharmaceuticals, Inc</orgName>
								<address>
									<addrLine>110 Allen Road</addrLine>
									<postCode>07920</postCode>
									<settlement>Basking Ridge</settlement>
									<region>NJ</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Garen</forename><surname>Manvelian</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution">Regeneron Pharmaceuticals, Inc</orgName>
								<address>
									<addrLine>777 Old Saw Mill River Road</addrLine>
									<postCode>10591</postCode>
									<settlement>Tarrytown</settlement>
									<region>NY</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-08-29">29 August 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">304D0CA8790BAC9168EBC75BC58BAEFA</idno>
					<idno type="DOI">10.1093/eurheartj/ehw497</idno>
					<note type="submission">Received 29 June 2016; revised 3 August 2016; accepted 11 August 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:24+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Aim</head><p><s>To evaluate the effect of alirocumab on frequency of standard apheresis treatments [weekly or every 2 weeks (Q2W)] in heterozygous familial hypercholesterolaemia (HeFH).</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Familial hypercholesterolaemia is characterized by raised low-density lipoprotein cholesterol (LDL-C) and premature onset of cardiovascular disease.</s><s>Without effective lipid-lowering treatment (LLT), adults with heterozygous familial hypercholesterolaemia (HeFH) have a very high risk of a coronary event by age 50.</s><s>Statins can reduce this risk, but patients still have an approximately two-fold excess of coronary heart disease mortality vs. the general population. <ref type="bibr" target="#b0">1</ref> Lipoprotein apheresis removes apoproteinB100-containing lipoproteins from the blood. <ref type="bibr" target="#b1">2</ref> It is generally regarded as a last-resort option for patients with progressive cardiovascular disease and persistently elevated LDL-C. <ref type="bibr" target="#b1">2</ref> Apheresis is expensive and can only be performed in specialized centres, <ref type="bibr" target="#b2">3</ref> the availability of which varies in different countries.</s><s>As LDL-C concentrations quickly return to pre-treatment levels, patients must undergo a regular weekly or every 2 weeks (Q2W) apheresis regimen, depending on the patient's LDL-C value and local practice. <ref type="bibr" target="#b3">4</ref></s><s>Lipoprotein apheresis acutely lowers the LDL-C concentration by 50-75%, but the time-averaged reduction approximates 30%.</s></p><p><s>Alirocumab is a fully human monoclonal antibody that binds PCSK9 and inhibits PCSK9-mediated hepatic catabolism of the lowdensity lipoprotein receptor.</s><s>]<ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref> These data showing robust decreases in LDL-C suggested that alirocumab may allow a reduction in the frequency of standard apheresis treatments (weekly or Q2W) or remove the need for apheresis in patients with HeFH.</s><s>Therefore, the objective of this study was to evaluate the effect of alirocumab 150 mg Q2W vs. placebo on the standardized rate of apheresis treatments in patients with HeFH.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>ODYSSEY ESCAPE (https://www.clinicaltrials.gov/ct2/show/NCT023</s><s>26220) was a randomized, double-blind, placebo-controlled, parallelgroup, phase 3 study in patients with HeFH undergoing regular weekly or Q2W lipoprotein apheresis.</s><s>The study was conducted at 14 sites in the United States and Germany; screening started in March 2015 and was completed in September 2015.</s></p><p><s>The study design has been published. <ref type="bibr" target="#b13">14</ref></s><s>The main study criteria are detailed in Supplementary material online, Table <ref type="table" target="#tab_0">S1</ref>.</s><s>Eligible patients had HeFH (diagnosed by genotyping or clinical criteria <ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b15">16</ref> ), had undergone consistent lipoprotein apheresis weekly for !4 weeks or Q2W for !8 weeks, and had maintained a stable background medical LLT, diet, and exercise level for !8 weeks.</s><s>Patients undergoing all lipoprotein apheresis techniques were recruited (for additional information, see Supplementary material online, Text S1). <ref type="bibr" target="#b13">14</ref> Patients with homozygous familial hypercholesterolaemia (FH) were excluded.</s><s>Patients continued to take their background LLT and remained on a stable diet and exercise regimen from screening until the end of treatment visits. <ref type="bibr" target="#b13">14</ref></s><s>he study was approved by the local institutional review boards, and was conducted according to the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and applicable local laws and regulations.</s><s>All patients provided written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Intervention</head><p><s>During the 2-week screening period, patients provided informed consent, were checked for eligibility, and underwent a lipid panel and other laboratory testing, safety evaluation, and dietary review. <ref type="bibr" target="#b13">14</ref></s><s>LDL-C was calculated using the Friedewald formula (for information on laboratory analyses, as well as the well-being analysis, see Supplementary material online, Text S1). <ref type="bibr" target="#b16">17</ref> Qualifying patients were randomly assigned (2:1, respectively) to receive alirocumab 150 mg or placebo subcutaneously Q2W for 18 weeks during the double-blind treatment period.</s><s>Randomization was done centrally using an interactive voice or web response system and a permutedblock design to ensure even distribution of treatment assignment.</s><s>Randomization was stratified by frequency of apheresis procedure (weekly or Q2W) and normal (&lt;30 mg/dL) or elevated (!30 mg/dL) lipoprotein (a) values.</s><s>Treatment injections (in 1-mL volume) were administered at the site by research staff using an autoinjector, starting on the day of randomization.</s><s>The drug or placebo was administered immediately after completion of the apheresis procedure on days when the two coincided.</s></p><p><s>The double-blind treatment period comprised two intervals: (phase 1) from day 1 to week 6, the apheresis rate was fixed according to the patient's established schedule (weekly or Q2W); (phase 2) from week 7 to week 18, the apheresis rate was adjusted based on the patient's LDL-C response to treatment, determined by blinded point-of-care testing.</s><s>Apheresis was not performed when the LDL-C value at that visit was !30% lower than the baseline (pre-apheresis) LDL-C value, as described previously. <ref type="bibr" target="#b13">14</ref></s><s>Site personnel and patients were blinded to the LDL-C value and treatment assignment, and only received an alert as to whether apheresis should be performed on the basis of coded and blinded point-of-care LDL-C results.</s></p><p><s>Patients in Germany who completed the double-blind treatment period were offered an optional open-label extension (to week 86) (results for these patients are not currently available).</s><s>The extension was not offered to patients in the United States because alirocumab is commercially available, but patients had the option to initiate clinical treatment with alirocumab or evolocumab.</s><s>Patients who were not eligible or who chose not to enter the extension were followed for 8 weeks after the end of the double-blind treatment period, or after premature discontinuation of study treatment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Outcome measures</head><p><s>The primary efficacy endpoint was the rate of apheresis treatments over 12 weeks (weeks 7 to 18), standardized according to the number of planned treatments for each individual patient.</s><s>Key secondary endpoints are listed in Supplementary material online, Table <ref type="table" target="#tab_1">S2</ref>.</s></p><p><s>Safety was assessed based on adverse event reports and laboratory analyses during the treatment-emergent adverse event (TEAE) period (defined as the time from the first dose of double-blind study treatment to the last injection plus 70 days [10 weeks], as alirocumab was anticipated to have a residual effect lasting for 10 weeks after the last injection).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>We estimated that a sample size of 63 patients (alirocumab 42: placebo 21) would have at least 85% power to detect a 33% difference in mean apheresis rates using a two-sided significance level and assuming a standard deviation (SD) of 40%. <ref type="bibr" target="#b13">14</ref></s><s>he primary efficacy analysis population was the primary intent-totreat (ITT) population, defined as all randomized patients.</s><s>The secondary efficacy analysis population was based on randomized patients who had atleast one pre-apheresis calculated LDL-C value before the first dose of study drug (or randomization, if the patient did not receive any study drug) and at least one calculated LDL-C value in one of the pre-apheresis analysis windows up to week 6.</s><s>The statistical analysis was conducted when the last patient completed all efficacy assessments at week 18.</s><s>LDL-C data were analysed post hoc using the <ref type="bibr">Kroon 18</ref> formula (see Supplementary material online, Text S1) to estimate the interval means of LDL-C in weeks 6-18 (after potential withdrawal of apheresis therapy).</s></p><p><s>The standardized rate of apheresis treatments was analysed through the rate of treatments received during the 12-week period (week 7 to week 18), divided by the number of planned treatments (6 for Q2W and 12 for weekly), using the ranked analysis of covariance (ANCOVA) model. <ref type="bibr" target="#b18">19</ref></s><s>The standardized apheresis rate could range from 0 to 1, with 0 indicating that the patient skipped all planned apheresis treatments between week 7 to week 18, and 1 indicating that the patient received all planned treatments.</s><s>A rate of 0.75 indicated that the patient received 75% of planned apheresis treatments (and skipped 25% of planned treatments).</s><s>Patient drop-outs were accounted for as described in Supplementary material online, Text S1.</s><s>The median treatment difference was determined using the Hodges-Lehmann estimation and 95% confidence intervals (CIs) using Moses distribution-free CI (see Supplementary material online, Text S1). <ref type="bibr" target="#b13">14</ref> We used a hierarchical inferential approach to control type I error.</s><s>As the primary endpoint analysis was significant at the 5% alpha level, key secondary efficacy endpoints were tested sequentially (see Supplementary material online, Table <ref type="table" target="#tab_1">S2</ref>). <ref type="bibr" target="#b13">14</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Seventy-six patients with HeFH undergoing regular weekly or Q2W lipoprotein apheresis provided consent to participate and were screened; 62 (71.6%) patients were eligible for randomization in the study.</s><s>Forty-one patients were randomly assigned to alirocumab and 21 to placebo (see Supplementary material online, Figure <ref type="figure" target="#fig_3">S1</ref>).</s><s>All randomized patients received double-blind study treatment and were included in the safety population.</s><s>Sixty patients completed the 6-week double-blind treatment period (40 [97.6%] in the alirocumab group and 20 [95.2%] in the placebo group) (i.e. when apheresis rate was determined by the patient's established schedule), and 57 completed the 18-week double-blind treatment period (37 [90.2%] and 20 [95.2%], respectively), when the apheresis schedule was determined by LDL-C value previously achieved.</s><s>Of the five (8.1%) patients who prematurely discontinued study treatment, one (4.8%)</s><s>was on placebo (withdrawn due to adverse events) and four (9.8%) were on alirocumab (two were withdrawn for adverse events and one for poor compliance, one patient withdrew consent).</s></p><p><s>The mean 6 SD age of the population was 58.7 6 9.7 years, 36 (58.1%) patients were men, and 60 (96.8%) were white.</s><s>The median (minimum, maximum) duration of apheresis treatments before entry into the study was 4.9 (0.5, 32.9) years.</s></p><p><s>The baseline characteristics were balanced between treatment groups (Table <ref type="table" target="#tab_0">1</ref> and Supplementary material online, Table <ref type="table" target="#tab_3">S3</ref>).</s><s>The mean calculated baseline LDL-C (at study entry) was 4.5 6 1.4 mmol/L (175.1 mg/dL) in the alirocumab group and 5.0 6 1.8 mmol/L (191.</s><s>6 mg/dL) in the placebo group (P ¼ 0.35).</s><s>Twenty-seven (43.5%) patients followed a weekly apheresis schedule at baseline and 35 (56.5%) patients followed a Q2W schedule.</s><s>The mean LDL-C value in patients undergoing weekly apheresis was 3.9 6 1.3 mmol/L (151.3 6 51.3 mg/dL) vs. 5.3 6 1.4 mmol/L (204.9 6 55.7 mg/dL) in patients undergoing Q2W apheresis.</s><s>Thirty-eight (61.3%) patients had normal baseline lipoprotein (a) levels (&lt;30 mg/dL) and 24 (38.7%) had elevated levels.</s><s>Thirty-four (54.8%) patients were taking a statin at screening, 19 (55.9%) of whom were on a maximum daily dose.</s><s>Baseline LDL-C values were 4.0 6 1.4 mmol/L (155.0 6 54.6 mg/dL) among statin-treated patients compared with 5.4 6 1.4 mmol/L (208.0 6 53.2 mg/dL) in patients not taking a statin.</s><s>Thirty patients (48.4%) were from Germany and 32 (51.6%) from the United States (see Supplementary material online, Table <ref type="table">S4</ref>).</s></p><p><s>The mean 6 SD duration of injection exposure was 17.4 6 2.3 weeks (8.6 6 1.3 injections) in the alirocumab group and 17.5 6 3.1 weeks (8.4 6 1.7 injections) in the placebo group.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Efficacy</head><p><s>The primary efficacy endpoint achieved statistically significant benefit in favour of alirocumab-treated patients, with a Hodges-Lehmann median estimate of the treatment difference vs. placebo of 0.75 (95% CI 0.67-0.83).</s><s>Therefore, alirocumab-treated patients had a 0.75 (75%) additional reduction in the standardized rate of apheresis treatments vs. placebo-treated patients (P &lt; 0.0001) (Table <ref type="table" target="#tab_1">2</ref>).</s><s>The median treatment difference in the standardized rate of apheresis treatments from week 7 to week 18, when apheresis treatment was determined by LDL-C concentration previously achieved, was 0.75 (95% CI 0.58-0.92)</s><s>for patients who had been undergoing weekly apheresis and 0.67 (95% CI 0.50-1.00)</s><s>for those on a Q2W schedule, in favour of alirocumab.</s></p><p><s>The median treatment difference in the standardized rate of apheresis treatments over the 4-week period (week 15 to week 18) was 0.50 (95% CI 0.50 -1.00; P &lt; 0.0001) in favour of alirocumab, indicating a 50% reduction in the standardized rate of apheresis treatments vs. placebo (Table <ref type="table" target="#tab_1">2</ref>).</s><s>The individual patient reductions in apheresis over the 12-week period are illustrated in Figure <ref type="figure" target="#fig_3">1A</ref>.</s><s>During this period, 63.4% of patients on alirocumab had no apheresis procedures, and 92.7% avoided at least half of the procedures (Figure <ref type="figure" target="#fig_3">1B</ref>).</s><s>The rate of apheresis treatments according to apheresis schedule is illustrated in Supplementary material online, Figure <ref type="figure" target="#fig_4">S2</ref>.</s><s>The standardized rate of apheresis treatments was analysed through the rate of treatments received during the 12-week period (week 7 to week 18), divided by the number of planned treatments (6 for Q2W and 12 for weekly).</s><s>One patient on a Q2W schedule was misstratified at the time of randomization; on the basis of the ITT approach, the data for this patient were included in the weekly group.</s></p><p><s>.  <ref type="figure" target="#fig_4">2</ref>).</s></p><p><s>The least square (LS) mean 6 standard error (SE) (95% CI) per cent change in pre-apheresis LDL-C from baseline at week 6 was -53.7 6 2.3 (-58.2 to -49.2) in the alirocumab group and 1.6 6 3.1 (-4.7 to 7.9) in the placebo group (LS mean 6 SE per cent difference -55.3 6 3.9, 95% CI -63.1 to -47.5; P &lt; 0.0001) (Figure <ref type="figure" target="#fig_4">2</ref> and Supplementary material online, Table <ref type="table">S5</ref>).</s><s>By week 18, the mean LDL-C value in the alirocumab group had risen slightly, to 2.9 mmol/L (110 mg/dL), compared with 4.9 mmol/L (191 mg/dL) in the placebo group (LS mean 6 SE per cent difference -46.4 6 7.9, 95% CI -62.3 to -30.5; P &lt; 0.0001) (Figure <ref type="figure" target="#fig_4">2</ref> and Supplementary material online, Table <ref type="table">S5</ref>).</s><s>Results for other selected key secondary endpoints are shown in Supplementary material online, Table <ref type="table">S5</ref>.</s><s>Results from the well-being analysis are given in Supplementary material online, Text S2 and Table <ref type="table">S6</ref>.</s></p><p><s>A cross-validation, comparing point-of-care LDL-C values with central laboratory values, showed that both measures were highly correlated (Pearson's correlation 0.86) (Supplementary material online, Text S3).</s></p><p><s>Per cent change from baseline to week 18 in lipoprotein (a) was -5.7% for alirocumab vs. -3.0%</s><s>for placebo among patients with normal baseline values, and 4.9% vs. 7.6%, respectively, in patients with elevated baseline values (Supplementary material online, Table <ref type="table">S7</ref>).</s><s>During weeks 7-18, when apheresis treatment could be withdrawn, alirocumab treatment was associated with a lower mean 6 SD time-averaged LDL-C value (using the Kroon formula <ref type="bibr" target="#b17">18</ref> ) over the course of the (potential) apheresis interval of 2. 4 6 1.3 mmol/L (92.7 6 50.2 mg/dL) vs. 3.8 6 1.7 mmol/L (146.</s><s>7 6 65.6 mg/dL) for placebo (P &lt; 0.0001).</s></p><p><s>In a post hoc analysis, the time-averaged LDL-C values in the alirocumab-treated patients were consistently lower than those in the placebo-treated patients (Supplementary material online, Figure <ref type="figure">S3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Safety</head><p><s>TEAEs were reported by 75.6% of patients in the alirocumab group and by 76.2% of patients in the placebo group, none of which were fatal (Table <ref type="table" target="#tab_3">3</ref>).</s><s>The rates of serious adverse events (9.8% for alirocumab and 9.5% for placebo) and events leading to treatment discontinuation (4.9% and 4.8%, respectively) were also similar in both groups.</s></p><p><s>Three patients (7.3%) in the alirocumab group and none in the placebo group had two consecutive pre-apheresis calculated LDL-C values &lt;0.7 mmol/L (25 mg/dL).</s><s>Two of these patients had at least one adverse event, one of which had several serious adverse events (pneumonia, acute myocardial infarction, acute respiratory failure, congestive heart failure, sepsis, and aortic valve stenosis).</s><s>Twentyseven patients (23 [56.1%] on alirocumab and 4 [19.0%] on placebo) had two consecutive LDL-C values &lt;0.7 mmol/L after apheresis, of which 15 (65.2%) and 2 (50.0%), respectively, had an adverse event.</s><s>None of the events was serious but one patient (4.3%) discontinued treatment with alirocumab.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The ODYSSEY ESCAPE study was conducted in HeFH patients who had been undergoing regular lipoprotein apheresis.</s><s>The study achieved the primary endpoint in the ITT population of a statistically significant 75% reduction in the standardized rate of apheresis in favour of alirocumab (P &lt; 0.0001).</s><s>The standardized rate of apheresis was at least halved in 39 of 41 (92.7%) patients on alirocumab, with 63.4% having no apheresis procedures during the 12-week period.</s><s>Patients receiving alirocumab had lower time-averaged LDL-C values than placebo-treated patients.</s></p><p><s>At week 6, the pre-apheresis LDL-C concentration was reduced by 53.7% in patients on alirocumab, in line with the anticipated reduction.</s><s>Consequently, the percentage of patients on apheresis at week 7 dropped markedly in the alirocumab group.</s><s>Whereas 15 of the 21 placebo-treated patients avoided some of their planned apheresis treatments, three placebo-treated patients achieved a !50% reduction in the apheresis rate.</s><s>The reasons for this reduction in the apheresis rate with placebo are unclear, but may reflect individual variation in LDL-C values, perhaps due to changes in diet or adherence to LLT, the small sample size, and the fact that patients were in a supervised clinical trial.</s></p><p><s>All of the patients in this study were at high cardiovascular risk and had taken LLT previously, including statins.</s><s>At screening, only 54.8% of the patients were taking a statin, 55.9% of whom were on a maximally tolerated dose.</s><s>A large proportion of the overall population reported a history of down-titration of statin treatment due to tolerability issues (43.5%) and 62.9% reported changing to a different statin.</s><s>Various reasons were given for not taking a statin or for not taking it at the maximum daily dose, ranging from muscle symptoms to anxiety about side-effects, and regional practices/local labelling, indicating that patients with HeFH on apheresis present a diverse and difficult-to-treat population, with limited treatment options.</s></p><p><s>Patients in the USA showed different characteristics to those in Germany, with higher baseline LDL-C, greater prevalence of statin intolerance, and a less frequent apheresis regimen.</s><s>In the USA, lipoprotein apheresis for HeFH is often only considered for patients who, after 6 months, do not have an adequate response to maximum tolerated drug therapy and have elevated LDL-C plus other cardiovascular risk factors. <ref type="bibr" target="#b19">20</ref></s><s>In Germany, where apheresis centres are more common, apheresis is considered within 12 months of failure of diet and LLT, and at a lower LDL-C threshold, and weekly is preferred to Q2W apheresis. <ref type="bibr" target="#b19">20</ref></s><s>Furthermore, recommendations for LDL-C lowering from Europe 3 are based on a risk-stratified treat-to-target approach, whereas US guidelines <ref type="bibr" target="#b20">21</ref> advocate a dose-adapted approach.</s><s>In view of the approach adopted in European guidelines, <ref type="bibr" target="#b2">3</ref> in which the target LDL-C value is &lt;1.8 mmol/L (70 mg/dL), German patients on alirocumab with LDL-C above this target value would still meet the criteria for apheresis.</s><s>Consequently, LLT with alirocumab may prove complementary to lipoprotein apheresis in patients with very high LDL-C or who fail to meet the target LDL-C value.</s></p><p><s>A small observational study involving three patients with HeFH on long-term apheresis, who ceased apheresis treatment and received single injections of evolocumab 140 mg Q2W subcutaneously over 7 weeks, reported similar results. <ref type="bibr" target="#b22">22</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Limitations</head><p><s>The present study was conducted in two countries, with patients showing markedly different baseline and treatment characteristics.</s><s>In order to account for these differences, the target level was based on per cent reduction from baseline in LDL-C rather than on achievement of a specific goal (e.g.</s><s>&lt;1.8 mmol/L[70 mg/dL]) for any given patient.</s><s>Thus, in some cases apheresis was interrupted despite the fact that specific LDL-cholesterol goals were not achieved.</s><s>Guideline-recommended threshold values may be achievable in individual patients through treatment with alirocumab alone or in combination with lipoprotein apheresis.</s><s>Furthermore, the study is limited by a relatively small sample size and the short trial duration.</s><s>However, there is no reason to believe that longer-term studies or larger sample sizes would provide different results.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Lipoprotein apheresis was discontinued in 63.4% of patients on alirocumab who were previously undergoing regular apheresis every 1 or 2 weeks, and the standardized rate was reduced by at least 50% in an additional 29.3% of patients.</s><s>PCSK9 inhibition maintained LDL-C at a significantly reduced plateau level as a function of antibody dose over time, whereas LDL-C levels following lipoprotein apheresis started to increase towards pre-procedure levels very rapidly regardless of the frequency of apheresis administration.</s><s>This difference between PCSK9 inhibition and apheresis translates into a cumulative area under the curve LDL-C benefit in favour of alirocumab, and may be of clinical significance over the long term.</s><s>Alirocumab was generally safe and well tolerated.</s><s>The findings from this study suggest a role for alirocumab in the overall management of patients with HeFH undergoing regular lipoprotein apheresis therapy, with the potential to avoid apheresis treatments or delay the requirement for such treatments.</s><s>from Regeneron, grants and personal fees from Sanofi, grants and personal fees from Amgen, grants and personal fees from Ionis, grants and</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Alirocumab in patients with HeFH undergoing lipoprotein apheresis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>....................................................................................................................................................................................................................</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>a</head><label></label><figDesc><div><p><s>There were no clinically or statistically significant between-group differences.b</s><s>Self-reported.</s><s>c 40-80 mg/day atorvastatin or 20-40 mg/day rosuvastatin.</s><s>d Colesevelam hydrochloride, colestipol, ezetimibe, fish oil, nicotinic acid, omega 3 fatty acids or omega-3-acid ethyl ester.</s><s>................................................................... ....................................................................................................................................................................................................................</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 1 (</head><label>1</label><figDesc><div><p><s>Figure 1 (A) Individual patients' reductions in standardized rate of apheresis treatments from week 7 to week 18; (B) Standardized rate of apheresis treatments from week 7 to week 18 (intent-totreat) by randomized treatment.</s><s>Two patients (one in each randomized treatment group) terminated study treatments before week 6, and their standardized apheresis rates were imputed as 1 (i.e.</s><s>100%).</s></p></div></figDesc><graphic coords="5,59.36,75.80,209.85,329.90" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 Pre-apheresis low-density lipoprotein cholesterol values (mean, with 95% CI) achieved at 2-weekly time-points (intent-to-treat analysis).</s><s>The arrow indicates the time from which apheresis treatments could be avoided, when a !</s><s>30% reduction in low-density lipoprotein cholesterol was achieved vs. baseline (pre-apheresis).</s><s>Values above the lines indicate LS mean low-density lipoprotein cholesterol values.</s><s>Values below week 6 and week 18 data points indicate LS mean (95% CI) per cent change from baseline.</s></p></div></figDesc><graphic coords="6,95.87,75.80,408.92,242.87" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head></head><label></label><figDesc><div><p><s>.................................................................................................</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Baseline characteristics (randomized patients) a</s></p></div></figDesc><table><row><cell>Characteristic</cell><cell>Alirocumab (n 5 41)</cell><cell>Placebo (n 5 21)</cell></row><row><cell>Age (years), mean 6 SD</cell><cell>59.5 6 9.2</cell><cell>57.0 6 10.5</cell></row><row><cell>Men, n (%)</cell><cell>26 (63.4)</cell><cell>10 (47.6)</cell></row><row><cell>Race, n (%) b</cell><cell></cell><cell></cell></row><row><cell>White</cell><cell>39 (95.1)</cell><cell>21 (100)</cell></row><row><cell>Black or African American</cell><cell>2 (4.9)</cell><cell>0</cell></row><row><cell>Body mass index (kg/m 2 ), mean 6 SD</cell><cell>30.5 6 5.0</cell><cell>30.3 6 6.2</cell></row><row><cell>Country, n (%)</cell><cell></cell><cell></cell></row><row><cell>Germany</cell><cell>20 (48.8)</cell><cell>10 (47.6)</cell></row><row><cell>United States</cell><cell>21 (51.2)</cell><cell>11 (52.4)</cell></row><row><cell>Previous PCI or CABG, n (%)</cell><cell>35 (85.4)</cell><cell>14 (66.7)</cell></row><row><cell>Time from hypercholesterolaemia diagnosis (years), mean 6 SD</cell><cell>13.3 6 12.9</cell><cell>15.2 6 14.0</cell></row><row><cell>Frequency of apheresis, n (%)</cell><cell></cell><cell></cell></row><row><cell>Weekly</cell><cell>18 (43.9)</cell><cell>9 (42.9)</cell></row><row><cell>Every 2 weeks</cell><cell>23 (56.1)</cell><cell>12 (57.1)</cell></row><row><cell>Time from first known apheresis treatment (years), median (IQR)</cell><cell>4.5 (0.5, 32.9)</cell><cell>5.3 (0.5, 27.3)</cell></row><row><cell>Background lipid-modifying therapy at randomization, n (%)</cell><cell></cell><cell></cell></row><row><cell>Any statin</cell><cell>19 (46.3)</cell><cell>13 (61.9)</cell></row><row><cell>High-intensity statin c</cell><cell>13 (31.7)</cell><cell>12 (57.1)</cell></row><row><cell>Any LLT d other than statins (with or without statin)</cell><cell>26 (63.4)</cell><cell>16 (76.2)</cell></row><row><cell>LDL-C (measured formula)</cell><cell>4.5 6 1.3 [174.0 6 51.4]</cell><cell>5.0 6 1.7 [195.0 6 66.9]</cell></row><row><cell>Range</cell><cell>1.4-6.8 [56-265]</cell><cell>2.3-8.1 [90-313]</cell></row><row><cell>Median (IQR)</cell><cell>4.6 (3.3:5.7)[176.0 (129.0:219.0)]</cell><cell>4.7 (3.6:6.2)[180.0 (140.0:240.0)]</cell></row><row><cell>LDL-C (Friedewald formula) (mmol/L) [mg/dL]</cell><cell>4.5 6 1.4 [175.1 6 54.6]</cell><cell>5.0 6 1.8 [191.6 6 68.9]</cell></row><row><cell>Range</cell><cell>1.4-7.1 [53-275]</cell><cell>2.1-8.2 [81-316]</cell></row></table><note><p><s>LDL-C at baseline, mean 6 SD or median (IQR) (mmol/L) [mg/dL] CABG, coronary artery bypass graft; IQR, interquartile range; LDL-C, low-density lipoprotein cholesterol; LLT lipid-lowering therapy; PCI, percutaneous coronary intervention; SD, standard deviation.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Primary study endpoint and key secondary endpoint</s></p></div></figDesc><table><row><cell></cell><cell cols="3">Alirocumab (n 5 41) Placebo (n 5 21) Alirocumab vs. placebo</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Hodges-Lehmann estimate</cell><cell>P value</cell></row><row><cell></cell><cell></cell><cell></cell><cell>of median treatment difference</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(95% Moses distribution-free CI)</cell><cell></cell></row><row><cell>Primary endpoint: Standardized rate of apheresis</cell><cell>0 (0, 100)</cell><cell>83 (42, 100)</cell><cell>0.75 (0.67-0.83)</cell><cell>&lt;0.0001</cell></row><row><cell>treatments over 12 weeks (from weeks 7 to 18), a</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>median (minimum, maximum), %</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Key secondary endpoint: Standardized rate</cell><cell>0 (0, 0)</cell><cell>100 (50, 100)</cell><cell>0.50 (0.50-1.00)</cell><cell>&lt;0.0001</cell></row><row><cell>of apheresis treatments during week 15 to</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>week 18, a median (minimum, maximum), %</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>CI, confidence interval; Q2W, every 2 weeks.</s><s>a</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</s></p></div></figDesc><table><row><cell>The mean pre-apheresis LDL-C value decreased from 4.5 mmol/L</cell></row><row><cell>(175 mg/dL) at baseline to 2.3 mmol/L (90 mg/dL) at week 6 in the</cell></row><row><cell>alirocumab group; corresponding data for patients in the placebo</cell></row><row><cell>group are 5.0 mmol/L (192 mg/dL) and 4.8 mmol/L (185 mg/dL)</cell></row><row><cell>(Figure</cell></row></table><note><p><s>. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3</head><label>3</label><figDesc><div><p><s>TEAEs a and laboratory parameters (safety population) at 18 weeks Continued ................................................................................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</s><s>.personal fees from Genzyme, personal fees from Duke, personal fees from Esperion, personal fees from Eliaz Therapeutics, personal fees from Alexion, grants from Pfizer, grants from Catabasis, grants from Novartis, grants from Kaneka, personal fees from Aegerion, personal fees from Amarin, personal fees from Lilly, outside the submitted work.</s><s>Dr Parhofer reports grants and personal fees from Sanofi/Regeneron, during the conduct of the study; personal fees from Sanofi-Aventis, grants and personal fees from Regeneron, personal fees from Aegerion, grants and personal fees from Merck, Sharp &amp; Dohme, personal fees from Amgen, personal fees from Boehringer Ingelheim, personal fees from Pfizer, outside the submitted work.</s><s>Dr Babirak reports other from Sanofi, other from Amgen, during the conduct of the study; other from Sanofi, other from Amgen, outside the submitted work.</s><s>Dr Cornier reports grants from Regeneron, outside the submitted work.</s><s>Dr Duell reports grants from Regeneron, during the conduct of the study; personal fees from Regeneron, personal fees from Amgen, personal fees from Kaneka, outside the submitted work.</s><s>Dr Hohenstein reports personal fees from Amgen GmBH, grants and personal fees from Kaneka Pharma Europe N.V., personal fees from Miltenyi Biotec GmbH, personal fees from Fresenius Medical Care GmbH, grants and personal fees from B. Braun Avitum, personal fees from Sanofi-Aventis, grants and personal fees from Novartis, personal fees from Alexion Pharma, outside the submitted work.</s><s>Dr Leebmann reports nothing to disclose.</s><s>Dr Ramlow reports grants and personal fees from Amgen, grants and personal fees from Fresenius, grants and personal fees from Kaneka, personal fees from Aegerion, personal fees from B. Braun, personal fees from Merck Sharp &amp; Dohme, personal fees from Regeneron Pharmaceuticals Inc., personal fees from Sanofi, outside the submitted work.</s><s>Dr Schettler reports support for lectures from Sanofi-Aventis.</s><s>Dr Simha reports nothing to disclose.</s><s>Dr Steinhagen-Thiessen reports nothing to disclose.</s><s>Dr Thompson reports other from Regeneron, other from Sanofi, other from Amgen, outside the submitted work.</s><s>Dr Vogt reports other from Sanofi/Regeneron Pharmaceuticals, during the conduct of the study; other from Sanofi/Regeneron Pharmaceuticals, other from Sanofi/Regeneron Pharmaceuticals, outside the submitted work.</s><s>Dr von Stritzky is an employee of Sanofi Germany.</s><s>Dr Du is an employee of Regeneron Pharmaceuticals Inc. Dr Manvelian is an employee of Regeneron Pharmaceuticals Inc.</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Table 3 Continued</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>Alirocumab</cell><cell>Placebo</cell></row><row><cell></cell><cell>Alirocumab</cell><cell>Placebo</cell><cell></cell><cell>(n 5 41)</cell><cell>(n 5 21)</cell></row><row><cell></cell><cell>(n 5 41)</cell><cell>(n 5 21)</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>Laboratory parameters, n (%)</cell><cell></cell><cell></cell></row><row><cell>Any TEAE, n (%)</cell><cell>31 (75.6)</cell><cell>16 (76.2)</cell><cell cols="2">Alanine aminotransferase &gt; 3 Â ULN 0</cell><cell>0</cell></row><row><cell>Treatment-emergent serious</cell><cell>4 (9.8)</cell><cell>2 (9.5)</cell><cell>Creatine kinase &gt; 3 Â ULN</cell><cell>3 (7.3)</cell><cell>0</cell></row><row><cell>adverse event, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TEAE leading to death, n (%) TEAE leading to treatment</cell><cell>0 2 (4.9)</cell><cell>0 1 (4.8)</cell><cell cols="3">TEAE, treatment-emergent adverse event; ULN, upper limit of normal. a TEAEs are adverse events that developed or worsened or became serious dur-ing the TEAE period.</cell></row><row><cell>discontinuation, n (%)</cell><cell></cell><cell></cell><cell cols="3">b Alanine aminotransferase increased, liver function test abnormal, blood creatine</cell></row><row><cell>TEAEs by system organ class</cell><cell></cell><cell></cell><cell>phosphokinase increased.</cell><cell></cell><cell></cell></row><row><cell>occurring in ! 2% of patients</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>in either group, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>General disorders and</cell><cell>13 (31.7)</cell><cell>4 (19.0)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>administration site conditions</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Musculoskeletal and connective</cell><cell>13 (31.7)</cell><cell>4 (19.0)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>tissue disorders</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Infections and infestations</cell><cell>12 (29.3)</cell><cell>8 (38.1)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Gastrointestinal disorders</cell><cell>10 (24.4)</cell><cell>3 (14.3)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Injury, poisoning and</cell><cell>8 (19.5)</cell><cell>3 (14.3)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>procedural complications</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Respiratory, thoracic and</cell><cell>8 (19.5)</cell><cell>2 (9.5)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>mediastinal disorders</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nervous system disorders</cell><cell>7 (17.1)</cell><cell>1 (4.8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Laboratory investigations b</cell><cell>5 (12.2)</cell><cell>3 (14.3)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Cardiac disorders</cell><cell>4 (9.8)</cell><cell>3 (14.3)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Skin and subcutaneous</cell><cell>4 (9.8)</cell><cell>1 (4.8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>tissue disorders</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Blood and lymphatic</cell><cell>2 (4.9)</cell><cell>1 (4.8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>system disorders</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Metabolism and nutrition disorders</cell><cell>2 (4.9)</cell><cell>1 (4.8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Psychiatric disorders</cell><cell>2 (4.9)</cell><cell>1 (4.8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vascular disorders</cell><cell>1 (2.4)</cell><cell>2 (9.5)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Immune system disorders</cell><cell>1 (2.4)</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Ear and labyrinth disorders</cell><cell>1 (2.4)</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Reproductive system and</cell><cell>1 (2.4)</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell>breast disorders</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Eye disorders</cell><cell>0</cell><cell>1 (4.8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>TEAEs occurring in ! 5% of</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>patients in either group or</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>TEAEs of interest, n (%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Fatigue</cell><cell>6 (14.6)</cell><cell>2 (9.5)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nasopharyngitis</cell><cell>4 (9.8)</cell><cell>2 (9.5)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Diarrhoea</cell><cell>4 (9.8)</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Myalgia</cell><cell>4 (9.8)</cell><cell>1 (4.8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Upper respiratory tract infection</cell><cell>3 (7.3)</cell><cell>4 (19.0)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Headache</cell><cell>3 (7.3)</cell><cell>1 (4.8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Arthralgia</cell><cell>3 (7.3)</cell><cell>2 (9.5)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Nausea</cell><cell>2 (4.9)</cell><cell>3 (14.3)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Pruritus</cell><cell>2 (4.9)</cell><cell>1 (4.8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Back pain</cell><cell>2 (4.9)</cell><cell>2 (9.5)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Injection site reaction</cell><cell>1 (2.4)</cell><cell>0</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Palpitations</cell><cell>0</cell><cell>2 (9.5)</cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>. . . . . . . . . . . . . . . . . .</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank the patients, study coordinators and investigators, and the following persons from the sponsors for their contributions to critical review of the manuscript: Regeneron: William J. Sasiela, PhD, Robert, Pordy, MD, Johanna Mendoza, BSc, and Carol Hudson, BPharm; Sanofi: Jay Edelberg, MD, PhD, L. Veronica Lee, MD, Tu Nguyen, MD, and Michael Howard, MBA.</s><s>The authors thank Dr Claudia Stefanutti for her assistance in designing the ODYSSEY ESCAPE protocol.</s><s>Writing support was provided by Sophie K. Rushton-Smith, PhD, funded by Sanofi and Regeneron Pharmaceuticals, Inc.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary material</head><p><s>Supplementary material is available at European Heart Journal online.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>Sanofi and Regeneron Pharmaceuticals, Inc.</s><s>The sponsor was involved in the study design; in the writing of the report; and in the decision to submit the article for publication.</s><s>Funding to pay the Open Access publication charges for this article was provided by Sanofi and Regeneron Pharmaceuticals, Inc.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest: Dr Moriarty reports grants and personal fees</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Reductions in all-cause, cancer, and coronary mortality in statintreated patients with heterozygous familial hypercholesterolaemia: a prospective registry study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Neil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Betteridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Capps</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Mcdowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Durrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Seed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Humphries</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="2625" to="2633" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Quality of life in patients treated with lipoprotein apheresis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rosada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kassner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Banisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Steinhagen-Thiessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vogt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Lipidol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="323" to="329" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>e6</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Reiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Catapano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Backer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Graham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Taskinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Wiklund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Agewall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Alegria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chapman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Durrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Erdine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Halcox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hobbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kjekshus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Filardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Riccardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Storey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Esc/</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1769" to="1818" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Manag Care Pharm</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="139" to="149" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Taskinen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Ginsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Kastelein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Colhoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Merlet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pordy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Baccara-Dinet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="55" to="61" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Cannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Cariou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Blom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mckenney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lorenzato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pordy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Chaudhari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Colhoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Odyssey</forename><surname>Combo Ii</surname></persName>
		</author>
		<author>
			<persName><surname>Investigators</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1186" to="1194" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>Bays</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gaudet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Gouni-Berthold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hanotin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Donahue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="3140" to="3148" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kereiakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Cannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lorenzato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pordy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Chaudhari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Colhoun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">169</biblScope>
			<biblScope unit="page" from="906" to="915" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Kastelein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">N</forename><surname>Ginsberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Langslet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Hovingh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ceska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dufour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Blom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Civeira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krempf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lorenzato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pordy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Baccara-Dinet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Gipe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Geiger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Farnier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="2996" to="3003" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mckenney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hanotin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Asset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Stein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="page" from="1891" to="1900" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mckenney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Koren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kereiakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hanotin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Ferrand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Stein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="2344" to="2353" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Efficacy and safety of alirocumab in reducing lipids and cardiovascular events</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Farnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krempf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bergeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Luc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Averna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Stroes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Langslet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Raal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">El</forename><surname>Shahawy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Koren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Lepor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Lorenzato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pordy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Chaudhari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kastelein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Odyssey</forename><surname>Long Term</surname></persName>
		</author>
		<author>
			<persName><surname>Investigators</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">372</biblScope>
			<biblScope unit="page" from="1489" to="1499" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gipe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bergeron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gaudet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dufour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pordy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="page" from="29" to="36" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: rationale and design of the ODYSSEY ESCAPE trial</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Moriarty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Parhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Babirak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Degoma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">B</forename><surname>Duell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hohenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ramlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Simha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Steinhagen-Thiessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vogt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Von Stritzky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Manvelian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Lipidol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="627" to="634" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Scientific Steering Committee on behalf of the Simon Broome Register Group</title>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">303</biblScope>
			<biblScope unit="page" from="893" to="896" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
	<note>Risk of fatal coronary heart disease in familial hypercholesterolaemia</note>
</biblStruct>

<biblStruct xml:id="b15">
	<monogr>
		<title level="m" type="main">Report of a second WHO Consultation</title>
		<ptr target="http://whqlibdoc.who.int/hq/1999/WHO_HGN_FH_CONS_99.2.pdf?ua¼1" />
		<imprint>
			<date type="published" when="1998-07-20">1998. 20 July 2016</date>
			<biblScope unit="page">16</biblScope>
		</imprint>
	</monogr>
	<note>Familial Hypercholesterolemia (FH)</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Friedewald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Fredrickson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="499" to="502" />
			<date type="published" when="1972">1972</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Kroon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Van't Hof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Demacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Stalenhoef</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="519" to="526" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" type="main">Categorical Data Analysis Using the SAS System</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Stokes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Koch</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000">2000</date>
			<publisher>SAS Institute Inc</publisher>
			<pubPlace>Cary, NC</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Manag Care Pharm</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="139" to="149" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Robinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Lichtenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bairey</forename><surname>Merz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">N</forename><surname>Blum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Eckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Lloyd-Jones</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Mcbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Shero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Watson</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Eddleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Jarrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Labresh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nevo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wnek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Halperin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Bozkurt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Brindis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Curtis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Demets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hochman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Kovacs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ohman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Pressler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Sellke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Tomaselli</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">American College of Cardiology/American Heart Association Task Force on Practice Guidelines</title>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines</title>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="S1" to="45" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Lappegard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Enebakk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Thunhaug</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hovland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">251</biblScope>
			<biblScope unit="page" from="119" to="123" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
